258 related articles for article (PubMed ID: 19275673)
1. The endocannabinoid system: a promising target for the management of type 2 diabetes.
Scheen AJ
Curr Protein Pept Sci; 2009 Feb; 10(1):56-74. PubMed ID: 19275673
[TBL] [Abstract][Full Text] [Related]
2. CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.
Scheen AJ
J Neuroendocrinol; 2008 May; 20 Suppl 1():139-46. PubMed ID: 18426513
[TBL] [Abstract][Full Text] [Related]
3. Cannabinoid-1 receptor antagonists in type-2 diabetes.
Scheen AJ
Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):535-53. PubMed ID: 18054734
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
5. Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus.
Hollander P
Am J Med; 2007 Feb; 120(2 Suppl 1):S18-28; discussion S29-32. PubMed ID: 17296341
[TBL] [Abstract][Full Text] [Related]
6. The endocannabinoid system: a new target for the regulation of energy balance and metabolism.
Després JP
Crit Pathw Cardiol; 2007 Jun; 6(2):46-50. PubMed ID: 17667864
[TBL] [Abstract][Full Text] [Related]
7. [CB1 receptor inhibition and glucose metabolism: role of rimonabant in type 2 diabetes].
Scheen AJ; Paquot N; Van Gaal LF
Rev Med Suisse; 2008 Aug; 4(168):1812-7. PubMed ID: 18814765
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of cannabinoid receptors and glucose metabolism.
Scheen AJ; Paquot N
Curr Opin Clin Nutr Metab Care; 2008 Jul; 11(4):505-11. PubMed ID: 18542014
[TBL] [Abstract][Full Text] [Related]
9. Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders.
Scheen AJ; Paquot N
Best Pract Res Clin Endocrinol Metab; 2009 Feb; 23(1):103-16. PubMed ID: 19285264
[TBL] [Abstract][Full Text] [Related]
10. Rimonabant: the role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patients.
Dibble CT; Gelfand EV; Cannon CP
Curr Atheroscler Rep; 2007 Nov; 9(5):359-66. PubMed ID: 18001618
[TBL] [Abstract][Full Text] [Related]
11. An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity.
Christopoulou FD; Kiortsis DN
J Clin Pharm Ther; 2011 Feb; 36(1):10-8. PubMed ID: 21198716
[TBL] [Abstract][Full Text] [Related]
12. The endocannabinoid system as a novel approach for managing obesity.
Lillo JL
J Am Osteopath Assoc; 2007 Apr; 107(4 Suppl 2):S12-20. PubMed ID: 17784530
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.
Van Gaal L; Pi-Sunyer X; Després JP; McCarthy C; Scheen A
Diabetes Care; 2008 Feb; 31 Suppl 2():S229-40. PubMed ID: 18227491
[TBL] [Abstract][Full Text] [Related]
14. Effects of CB1 antagonist on the control of metabolic functions in obese type 2 diabetic patients.
Lafontan M; Piazza PV; Girard J
Diabetes Metab; 2007 Apr; 33(2):85-95. PubMed ID: 17418607
[TBL] [Abstract][Full Text] [Related]
15. Rimonabant: endocannabinoid inhibition for the metabolic syndrome.
Wierzbicki AS
Int J Clin Pract; 2006 Dec; 60(12):1697-706. PubMed ID: 17109677
[TBL] [Abstract][Full Text] [Related]
16. [Cardiometabolic effects of rimonabant in obese/overweight subjects with dyslipidaemia or type 2 diabetes].
Scheen AJ; Van Gaal LF
Rev Med Liege; 2007 Feb; 62(2):81-5. PubMed ID: 17461296
[TBL] [Abstract][Full Text] [Related]
17. [Medication of the month. Rimonabant (Acomplia): first CB1 receptor antagonist of the endocannabinoid system].
Scheen AJ; Van Gaal LF
Rev Med Liege; 2008 Jan; 63(1):50-5. PubMed ID: 18303686
[TBL] [Abstract][Full Text] [Related]
18. Effect of blockage of the endocannabinoid system by CB(1) antagonism on cardiovascular risk.
Mach F; Montecucco F; Steffens S
Pharmacol Rep; 2009; 61(1):13-21. PubMed ID: 19307689
[TBL] [Abstract][Full Text] [Related]
19. Rehashing endocannabinoid antagonists: can we selectively target the periphery to safely treat obesity and type 2 diabetes?
Patti ME
J Clin Invest; 2010 Aug; 120(8):2646-8. PubMed ID: 20664166
[TBL] [Abstract][Full Text] [Related]
20. The endocannabinoid system and cardiometabolic risk: effects of CB1 receptor blockade on lipid metabolism.
Deedwania P
Int J Cardiol; 2009 Jan; 131(3):305-12. PubMed ID: 18715660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
